Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

Scarcell Therapeutics, an innovator in cell therapies to treat chronic degenerative inflammatory diseases, today announced the world's first patients treated with its Allogenic Gingival Fibroblast ...

The Chromebooks that Leon County students have been toting from school to home and back again will have to stay at school for some middle schoolers.

The University of York, one of the Russell Group universities, is set to launch its Mumbai campus next year, offering ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the introduction of United Arab Emirates (UAE) equities through two leading exchanges in one of the world’s ...

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –– Data ...

When Villanova hosted the first women’s Big 5 Classic tripleheader last year, the Wildcats intended to cap it off by winning the title. Instead, the Temple Owls spoiled the party plans and left the ...

The tribunal held that the resolution plan was invalid because several valuable properties were omitted from the Information Memorandum. The ruling emphasises that all assets must be valued and ...